Vinblastine and Interferon-Gamma Combination with and without 13-Cis Retinoic Acid for Patients with Advanced Renal Cell Carcinoma
Vinblastine and Interferon-Gamma Combination with and without 13-Cis Retinoic Acid for Patients with Advanced Renal Cell Carcinoma
复制标题
长春花碱和干扰素-γ 组合（含或不含 13-顺式视黄酸）治疗晚期肾细胞癌患者
DOI：
10.1159/000063806
复制
发表时间：
2002
期刊：
影响因子：
3.5
通讯作者：
o on behalf of the Hellenic Cooperative Oncology Gro
中科院分区：
文献类型：
--
作者：
C. Bacoyiannis;M. Dimopoulos;H. Kalofonos;C. Nicolaides;G. Aravantinos;D. Bafaloukos;G. Samelis;A. Onyenadum;C. Kiamouris;D. Skarlos;N. Pavlidis;A. Triantafillidis;P. Kosmidis;o on behalf of the Hellenic Cooperative Oncology Gro
背景资料：本研究旨在观察长春碱（VBL）联合干扰素-γ（IFN-γ）治疗晚期肾细胞癌（RCC）的疗效和毒副反应，并评价13-顺式维甲酸（13-cis retinoic acid，13-CRA）对RCC的增效作用。方法：29例患者被纳入第一试验（试验1），40例患者被纳入第二试验（试验2）。试验1中给予的治疗包括VBL 0.15 mg/kg i. v.每2周一次和IFN-γ 100 µg s.c.每周3次。在试验2中，治疗包括相同剂量的相同两种药物，加上口服13-CRA 40 mg/天。结果如下：在试验1中，3例（10.3%）患者完全缓解，3例（10.3%）患者部分缓解，8例（27.6%）患者疾病稳定，15例（51.7%）患者疾病进展。在试验2中，无完全缓解，但3例（7.5%）患者部分缓解。此外，15例（37.5%）患者病情稳定，14例（35%）患者病情进展。在试验1中，中位生存期为12.56个月（95% CI，6.8-18.3，范围0.59-42.49），中位至进展时间为3.21个月（95% CI，1.7-4.7，范围0.03-42.49）。在试验2中，中位生存期为9. 54个月（95% CI，5. 9 - 13. 1，范围0. 43 - 24. 1），中位至进展时间为3. 9个月（95% CI，0. 8 -7，范围0. 26 - 24. 1）。在试验1中，5例（17.2%）患者出现3级和4级粒细胞减少症，1例（3.4%）患者出现3级贫血。在试验2中，有3级毒性，5例（12.5%）患者发生粒细胞减少症，4例（10.0%）患者发生贫血，3例（7.5%）患者发生口腔炎，3例（7.5%）患者发生疲乏/不适，1例（2.5%）患者发生腹泻。两项研究均未发生中毒性死亡。结论：IFN-γ的使用并不增加VBL为基础的化疗的低应答。另外给予13-CRA与VBL和IFN-γ的组合不会增加该组合在晚期肾细胞癌患者中的疗效。需要新的活性剂来治疗患有这种疾病的患者。
Background: The aim of this study is firstly to determine the response rates and toxicity of two regimens containing vinblastine (VBL) in combination with interferon-gamma (IFN-γ) in the treatment of patients with advanced renal cell carcinoma (RCC), and secondly to evaluate the additional efficacy of 13-cis retinoic acid (13-CRA) in RCC. Methods: Twenty-nine patients were included in the first trial (Trial 1) and 40 in the second one (Trial 2). The therapy given in Trial 1 consisted of VBL 0.15 mg/kg i.v. every 2 weeks and IFN-γ 100 µg s.c. 3 times weekly. In Trial 2, the therapy consisted of the same two drugs, in the same doses, plus oral 13-CRA 40 mg/day. Results: In Trial 1 there were 3 (10.3%) patients with complete response, 3 (10.3%) patients with partial response, 8 (27.6%) patients with stable disease and 15 (51.7%) patients with progressive disease. In Trial 2, there was no complete response, however, 3 (7.5%) patients had partial response. Additionally, 15 (37.5%) patients maintained stable disease and 14 (35%) patients had progressive disease. In Trial 1, the median survival was 12.56 months (95% CI, 6.8–18.3, range 0.59–42.49) and the median time to progression was 3.21 months (95% CI, 1.7–4.7, range 0.03–42.49). In Trial 2, the median survival was 9.54 months (95% CI, 5.9–13.1, range 0.43–24.1) and the median time to progression was 3.9 months (95% CI, 0.8–7, range 0.26–24.1). In Trial 1, granulocytopenia grade 3 and 4 appeared in 5 (17.2%) patients and anaemia grade 3 in 1 (3.4%) patient. In Trial 2, there were grade 3 toxicities, as granulocytopenia in 5 (12.5%) patients, anemia in 4 (10.0%) patients, stomatitis in 3 (7.5%) patients, fatigue/malaise in 3 (7.5%) patients and 1 (2.5%) had diarrhea. No toxic deaths occurred in both studies. Conclusion: The use of IFN-γ does not enhance the low response of VBL-based chemotherapy. The additional administration of 13-CRA with the combination of VBL and IFN-γ does not add to the efficacy of this combination in patients with advanced renal cell carcinoma. New active agents are needed to treat patients with this disease.
登录
查看更多内容
长春碱-CCNU、三嗪和放线菌素治疗晚期肾细胞癌的 II 期研究。
DOI：
--
发表时间：
1981
期刊：
Cancer treatment reports
影响因子：
--
作者：
Hahn,RG;Begg,CB;Davis,T
通讯作者：
Davis,T
DOI：
--
发表时间：
1996-06
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
A. Hoffman;D. Engelstein;T. Bogenrieder;C. Papandreou;E. Steckelman;A. Dave;R. Motzer;E. Dmitrovsky;A. Albino;D. Nanus
通讯作者：
A. Hoffman;D. Engelstein;T. Bogenrieder;C. Papandreou;E. Steckelman;A. Dave;R. Motzer;E. Dmitrovsky;A. Albino;D. Nanus
影响因子：
45.3
作者：
Motzer, RJ;Murphy, BA;Mazumdar, M
通讯作者：
Mazumdar, M
阿霉素、博来霉素、长春新碱、环磷酰胺加卡介苗的联合化学免疫疗法治疗晚期肾癌。
DOI：
--
发表时间：
1981
期刊：
Cancer clinical trials
影响因子：
--
作者：
Dana,BW;Alberts,DS
通讯作者：
Alberts,DS